KaloBios, a Palo Alto company developing treatments for pseudomonas lung infections and autoimmune diseases including rheumatoid arthritis, is looking to raise up to $40 million in a third round of funding.

Newly-appointed KaloBios chief executive David Pritchard told VentureWire about his plans (sub required).